Purified populations of stem cells

Patent Number: 6852533

Date of First Priority Issue: Friday January 23rd, 1998

Date Issued: Tuesday February 8th, 2005

Assignee: Cornell Research Foundation, Inc. (Ithaca, NY); Sloan-Kettering Institute for Cancer Research (New York, NY); ImClone System Incorporated (New York, NY)

Inventors: Rafii, Shahin (Great Neck, NY); Witte, Larry (Stormville, NY); Moore, Malcolm A. S. (New York, NY)

From Class: Type

Comments: No comments

This is a powerful patent that covers essentially the endothelial precursor cell. The importance of endothelial precursors is their ability to induce angiogenesis.

The patent has claims on any CD34 + VEGF R+ cell, as well as CD133+, VEGF R+ endothelial stem cell.

Sources of these cells covered in the claims include circulating blood, cord blood, mobilized blood, and bone marrow.

The question is, the trials that are currently using autologous bone marrow cells for induction of angiogenesis...if the active cell is found to be CD34+ VEGF-R+, which it most likely is...then this patent will be very valuable to anyone operating in this area.